(PRWEB) January 17, 2012
Mesothelioma is a rare cancer caused by exposure to asbestos. Even though thousands have died from asbestos cancer and diseases, it is still a relatively unknown disease with no cure and often minimally effective treatments. The standard treatment for mesothelioma is usually a combination of surgery (if possible), chemotherapy and radiation therapy. The most common chemotherapy drugs used to treat mesothelioma are cisplatin and pemetrexed. Even these drugs, however, have shown little effectiveness in slowing the progression of disease or increasing survival times.
That’s why Clapper Patti Schweizer Mason (CPSM), an asbestos law firm based in California, is excited to announce a new drug, CBP501, shown to improve effectiveness of treatment for mesothelioma, was just awarded “Orphan Drug” status by the US Food and Drug Administration (FDA). CBP501, produced by a Japanese biopharmaceutical company, CanBas Co., Ltd., is a novel drug that enhances the anti-cancer cytotoxic activity when used with traditional chemotherapy combinations commonly used to treat mesothelioma. In more simple terms, CBP501 has been shown to increase mesothelioma cancer cell death by blocking the ability of cancer cells to transition completely through the cell cycle, thereby slowing the progression of the disease.
CanBas is a drug development biotech company devoted to developing more effective pharmaceuticals and therapies that improve efficacy of treatments and the overall health of those suffering from rare diseases. CanBas has been conducting Phase II Clinical Trials using CBP501 with mesothelioma patients for several years and were just granted “orphan drug” designation by the FDA.
According to the FDA, the “Orphan Drug Designation Program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S…”
It is estimated that over 200,000 people will die of mesothelioma worldwide this year, and about 3000 in the United States alone will be diagnosed with this terminal and incurable cancer. Because mesothelioma is considered to be a rare disease – so rare and deadly that it is difficult to get enough of a patient sample to conduct a Phase III clinical trial- it meets the FDA criteria for granting CBP501 “orphan drug” status.
By receiving this new designation, CanBas will be given tax reductions and also exclusive rights to CBP501 as a mesothelioma treatment for a period of up to seven years post-approval. The new status allows them to continue research and hopefully one day discover a cure for mesothelioma.
After reading the results from trials conducted so far, CPSM is hopeful that CBP501 can increase the effectiveness of mesothelioma treatments and extend both survival times and quality of life for their clients coping with mesothelioma. For more information on treatments or to speak with an experienced mesothelioma attorney about how to get financial help to pay for treatments, visit our website or call today: 1-800-440-4262.
For more than 30 years, Clapper Patti Schweizer & Mason has represented clients from all over the nation and won multimillion dollar verdicts on their and their family’s behalf. CPSM offers the highest quality of service and care to their clients, understanding how heartbreaking and challenging it is to cope with a diagnosis of mesothelioma. If you or a loved one has been diagnosed with mesothelioma, call today to speak free of charge directly with an expert attorney and receive a free case evaluation: 1-800-440-4262.